Doctors criticise leukaemia drug study into MabThera (also known as rituximab).

.

Three Australian oncologists say cancer treatment research published in one of the world's most prestigious medical journals may have been compromised by a drug company that funded the study.

They said publication of the research in The Lancet might have boosted the drug's perceived value to doctors and patients around the world, helping its manufacturer, Roche, make billions of dollars from the product.

To read the full story click HERE.

New Child leukaemia drug could boost survival rates

.

Scientists are hailing a chemotherapy drug found to significantly increase the survival chances of child leukaemia patients whose cancer has returned.

A Cancer Research UK study found giving mitoxantrone to children whose acute lymphoblastic leukaemia returned led to a 69% survival rate after three years.

The standard treatment offers a 45% survival rate, The Lancet study says.

To read the full article on the BBC website click HERE.